Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia

W. Jurczak, K. Chojnowski, J. Mayer, K. Krawczyk, BD. Jamieson, W. Tian, LF. Allen,

. 2018 ; 183 (3) : 479-490. [pub] 20180907

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze III, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035028

Avatrombopag, an oral thrombopoietin receptor agonist, was compared with placebo in a 6-month, multicentre, randomised, double-blind, parallel-group Phase 3 study, with an open-label extension phase, to assess the efficacy and safety of avatrombopag (20 mg/day) in adults with chronic immune thrombocytopenia (ITP) and a platelet count <30 × 109 /l (ClinicalTrials.gov identifier NCT01438840). The primary endpoint was the cumulative number of weeks of platelet response (platelet count ≥50 × 109 /l) without rescue therapy for bleeding; secondary endpoints included platelet response rate at day 8 and reductions in the use of concomitant medications. Amongst the 49 patients randomised, avatrombopag (N = 32) was superior to placebo (N = 17) in the median cumulative number of weeks of platelet response (12·4 vs. 0·0 weeks, respectively; P < 0·0001). At day 8, a greater platelet response rate was also observed for patients treated with avatrombopag compared with placebo (65·63% vs. 0·0%; P < 0·0001), and use of concomitant ITP medications was also reduced amongst patients receiving avatrombopag. The safety profile of avatrombopag was consistent with Phase 2 studies; the most common adverse events were headache and contusion. Overall, avatrombopag was well tolerated and efficacious for the treatment of chronic ITP.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035028
003      
CZ-PrNML
005      
20191008112816.0
007      
ta
008      
191007s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.15573 $2 doi
035    __
$a (PubMed)30191972
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Jurczak, Wojciech $u Department of Haematology, Jagiellonian University, Kraków, Poland.
245    10
$a Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia / $c W. Jurczak, K. Chojnowski, J. Mayer, K. Krawczyk, BD. Jamieson, W. Tian, LF. Allen,
520    9_
$a Avatrombopag, an oral thrombopoietin receptor agonist, was compared with placebo in a 6-month, multicentre, randomised, double-blind, parallel-group Phase 3 study, with an open-label extension phase, to assess the efficacy and safety of avatrombopag (20 mg/day) in adults with chronic immune thrombocytopenia (ITP) and a platelet count <30 × 109 /l (ClinicalTrials.gov identifier NCT01438840). The primary endpoint was the cumulative number of weeks of platelet response (platelet count ≥50 × 109 /l) without rescue therapy for bleeding; secondary endpoints included platelet response rate at day 8 and reductions in the use of concomitant medications. Amongst the 49 patients randomised, avatrombopag (N = 32) was superior to placebo (N = 17) in the median cumulative number of weeks of platelet response (12·4 vs. 0·0 weeks, respectively; P < 0·0001). At day 8, a greater platelet response rate was also observed for patients treated with avatrombopag compared with placebo (65·63% vs. 0·0%; P < 0·0001), and use of concomitant ITP medications was also reduced amongst patients receiving avatrombopag. The safety profile of avatrombopag was consistent with Phase 2 studies; the most common adverse events were headache and contusion. Overall, avatrombopag was well tolerated and efficacious for the treatment of chronic ITP.
650    _2
$a dospělí $7 D000328
650    _2
$a chronická nemoc $7 D002908
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a počet trombocytů $7 D010976
650    _2
$a idiopatická trombocytopenická purpura $x krev $x farmakoterapie $7 D016553
650    _2
$a receptory thrombopoetinu $x agonisté $x krev $7 D053628
650    _2
$a thiazoly $x aplikace a dávkování $x škodlivé účinky $7 D013844
650    _2
$a thiofeny $x aplikace a dávkování $x škodlivé účinky $7 D013876
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Chojnowski, Krzysztof $u Department of Haemostasis Disorders, Medical University of Łódź, Łódź, Poland.
700    1_
$a Mayer, Jiří $u Department of Internal Medicine, Haematology and Oncology, University Hospital Brno, Jihlavská, Czech Republic.
700    1_
$a Krawczyk, Katarzyna $u Department of Haematology, Jagiellonian University, Kraków, Poland.
700    1_
$a Jamieson, Brian D $u Dova Pharmaceuticals, Durham, NC, USA.
700    1_
$a Tian, Wei $u Dova Pharmaceuticals, Durham, NC, USA.
700    1_
$a Allen, Lee F $u Dova Pharmaceuticals, Durham, NC, USA.
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 183, č. 3 (2018), s. 479-490
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30191972 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191008113233 $b ABA008
999    __
$a ok $b bmc $g 1451688 $s 1073578
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 183 $c 3 $d 479-490 $e 20180907 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace